1B-LSD: Difference between revisions

Line 1:

'''1-Butanoyl-''d''-lysergic acid diethylamide''' (also known as '''1B-LSD''') is a novel [[Psychoactive class::psychedelic]] substance of the [[Chemical class::lysergamide]] class.

1B-LSD is closely related to [[LSD]] and [[1P-LSD]] and is reported to produce near-identical effects. 1B-LSD has been found to be around 14% as potent as LSD and expresses itself at the same 5-HT<sub>2A</sub> receptor.<ref name=":0">Brandt, Simon D., et al. "Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐d‐lysergic acid diethylamide (1B‐LSD)." ''Drug testing and analysis'' 11.8 (2019): 1122-1133. https://doi.org/10.1002/dta.2613</ref>

The original synthesis date of 1B-LSD is ~~unknown~~. Unlike most [[research chemicals]], 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online [[research chemical]] market.

The original synthesis date of 1B-LSD is not known. Unlike most [[research chemicals]], 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online [[research chemical]] market.

User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a [[prodrug]] for LSD.<ref name=":1">Wagmann, Lea, et al. "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures." ''Analytical and bioanalytical chemistry'' 411.19 (2019): 4751-4763.https://doi.org/10.1007/s00216-018-1558-9</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration. Characteristics effects include [[geometry|geometric visual hallucinations]], [[time distortion]], [[introspection|enhanced introspection]], and [[ego loss]]. Its classical psychedelic effects and favorable tolerability has led it to become popular among novel psychoactive substance users who use it interchangeably with LSD.

[[Subjective effects]] include [[visual geometry]], [[hallucinatory states]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[increased music appreciation]], [[euphoria]], and [[ego loss]]. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a [[prodrug]] for LSD.<ref name=":1">Wagmann, Lea, et al. "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures." ''Analytical and bioanalytical chemistry'' 411.19 (2019): 4751-4763.https://doi.org/10.1007/s00216-018-1558-9</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is presumed to have a similar toxicity and risk profile as [[LSD]], although no evidence currently exists to support this. It is highly advised to use [[harm reduction practices]] if using this substance.

@@ Line 1: / Line 1: @@
 {{SummarySheet}}
 {{SubstanceBox/1B-LSD}}
 '''1-Butanoyl-''d''-lysergic acid diethylamide''' (also known as '''1B-LSD''') is a novel [[Psychoactive class::psychedelic]] substance of the [[Chemical class::lysergamide]] class.
 B-LSD is closely related to [[LSD]] and [[1P-LSD]] and is reported to produce near-identical effects. 1B-LSD has been found to be around 14% as potent as LSD and expresses itself at the same 5-HT<sub>2A</sub> receptor.<ref name=":0">Brandt, Simon D., et al. "Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐d‐lysergic acid diethylamide (1B‐LSD)." ''Drug testing and analysis'' 11.8 (2019): 1122-1133. https://doi.org/10.1002/dta.2613</ref>
-The original synthesis date of 1B-LSD is unknown. Unlike most [[research chemicals]], 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online [[research chemical]] market.
+The original synthesis date of 1B-LSD is not known. Unlike most [[research chemicals]], 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online [[research chemical]] market.
-User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a [[prodrug]] for LSD.<ref name=":1">Wagmann, Lea, et al. "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures." ''Analytical and bioanalytical chemistry'' 411.19 (2019): 4751-4763.https://doi.org/10.1007/s00216-018-1558-9</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration. Characteristics effects include [[geometry|geometric visual hallucinations]], [[time distortion]], [[introspection|enhanced introspection]], and [[ego loss]]. Its classical psychedelic effects and favorable tolerability has led it to become popular among novel psychoactive substance users who use it interchangeably with LSD.
+[[Subjective effects]] include [[visual geometry]], [[hallucinatory states]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[increased music appreciation]], [[euphoria]], and [[ego loss]]. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a [[prodrug]] for LSD.<ref name=":1">Wagmann, Lea, et al. "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures." ''Analytical and bioanalytical chemistry'' 411.19 (2019): 4751-4763.https://doi.org/10.1007/s00216-018-1558-9</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration.
 Very little data exists about the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is presumed to have a similar toxicity and risk profile as [[LSD]], although no evidence currently exists to support this. It is highly advised to use [[harm reduction practices]] if using this substance.